Shire Orphan Therapies Gmbh

Jpt Peptide Technologies Gmbh

Baxalta Gmbh

Biontech Se

Baxter International Inc.

Takeda Pharmaceutical Company Limited

Baxter Healthcare Sa

Alcon Research, Ltd.

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Shire Orphan Thereapies Gmbh

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh

Biontech Ag

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Jerini Ag

Ulf Reimer

Ulrich Reineke

Gerd Hummel

Frank Osterkamp

Uwe Richter

Edgar Specker

Heiko Hawlisch

Tobias Knaute

Bernadett Simon

Markus Woischnik

Mark R Hellberg

Friedrich Scheiflinger

Michael Dockal

Hartmut Ehrlich

Eberhard Schneider

Thomas Polakowski

Karsten Schnatbaum

Ugur Sahin

Markus Fiedler

Dirk Scharn

Hans-Ulrich Schmoldt

Matin Daneschdar

Matthias Paschke

Christoph Gibson

Elsa Locardi

Jens Schneider-Mergener

Soren Panse

Laurence Jobron

Laura Marie Kring

Liying Dong

Laura-Marie Kring (née Plum)

Mark R Helberg

Thomas Tradler

Jochen Pfeifer

Mike Schutkowski

Laura-Marie Plum

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3&#x3b5;). These molecules compete with CD3&#x3b5; for binding to a CD3&#x3b5; binding domain. e.g. a CD3&#x3b5; binding domain of an antibody, and are capable of detecting antibodies against CD3&#x3b5;. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3&#x3b5; antibody purification and the detection of anti-CD3&#x3b5; antibodies in biological samples.

Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

TFPI inhibitors and methods of use

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Peptide mimotopes of claudin 18.2 and uses thereof

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

NPR-B agonists

Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.

Cyclic peptide-based NPR-B agonists

The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims. 

8-oxy-quinoline derivatives as bradykinin B2 receptor modulators

The invention relates to a method for determining the substrate specificity of an enzymatic activity comprising the following steps: providing an assembly comprising a plurality of amino acid sequences on a planar surface of a support material, whereby the amino acids are directionally immobilized; contacting and/or incubating of an enzymatic activity with the assembly; and detection of a reaction between one of the amino acid sequences that are immobilized on the assembly and the enzymatic activity. According to the invention, during the reaction of the enzymatic activity with the assembly, a change in the molecular weight of at least one of the amino acid sequences takes place.

Method for determining the substrate specificity of an enzyme

Growing community of inventors

Berlin, Germany

Ulf Reimer